Authorized purpose: Quantitative single-timepoint or longitudinal analysis of lesion ROIs on adult PET/CT, including volume, density, and tracer-uptake changes, with a report used as an adjunct to local image interpretation.
Clinical role
Centralized quantitative ROI segmentation, registration, longitudinal change analysis, and report generation as an adjunct to local interpretation; clinicians responsible for patient care or local image interpretation do not directly operate the device.
Images and patients
PET/SPECT/Nuclear Medicine · Whole body and lesion regions of interest
Key limitation
Keep in mind: The device is not intended to diagnose disease, replace CT or PET/CT interpretation, recommend treatment, or replace professional judgment. Binary patient-level progression or non-progression decisions are not established without multidisciplinary review; care-relevant discrepancies require subject-matter review and neutral or blinded adjudication. The stated age, tracer, and timepoint conditions apply.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Quantitative single-timepoint or longitudinal analysis of lesion ROIs on adult PET/CT, including volume, density, and tracer-uptake changes, with a report used as an adjunct to local image interpretation.
Which images or clinical context are in scope?Modality: PET/SPECT/Nuclear Medicine Anatomy or clinical context: Whole body and lesion regions of interest Input: CT and PET/CT volumetric images supported by ACR/NEMA DICOM 3.0, with ROIs identified by the software or imported from validated tools or qualified manual contouring. Multi-timepoint use recommends adult PET/CT after FDG with the second FDG administration no more than 12 months after the first; single-timepoint use also covers FDG-, PSMA-, or SSTR-targeted PET drugs per approved labeling.
Who uses it?Intended users: Trained medical professionals including oncologists, nuclear radiologists or physicians, medical imaging technologists, dosimetrists, and physicists; the report is generated by the manufacturer and signed by a U.S. board-certified physician qualified in nuclear radiology or medicine.
What does the software produce?Output: A TRAQinform Report with ROI anatomic location, contours and 2D/3D renderings, volumes and volume changes, CT radio-density measures and changes, PET SUVmax/SUVtotal/SUVmean/SUVhetero measures and changes, heterogeneity measures, and computed classification of quantitative FDG ROI changes.
What is its most important limitation?Key limitation: The device is not intended to diagnose disease, replace CT or PET/CT interpretation, recommend treatment, or replace professional judgment. Binary patient-level progression or non-progression decisions are not established without multidisciplinary review; care-relevant discrepancies require subject-matter review and neutral or blinded adjudication. The stated age, tracer, and timepoint conditions apply.
Clinical takeaway. Clinical role: Quantitative single-timepoint or longitudinal analysis of lesion ROIs on adult PET/CT, including volume, density, and tracer-uptake changes, with a report used as an adjunct to local image interpretation.
Evidence takeaway. Evidence from the reviewed source record: FDA testing included component verification, test-retest analysis, and a pivotal reader study. Test-retest used 31 non-small-cell-lung-cancer patients with two FDG PET/CT studies within one week; limits of repeatability were SUVmax -27.0% to 56.8%, SUVmean -20.2% to 38.5%, SUVtotal -54.1% to 144.5%, and volume -52.6% to 113.9%. The pivotal study used 103 patients with two sequential scans, three oncologist evaluators, and scans from at least 10 imaging centers in at least 3 U.S. states. In a 32-patient reevaluation subset, the 95% CI for overall percent agreement was 41%-76%, positive percent agreement was 14/18 (78%), and negative percent agreement was 5/14 (36%); ROI-level agreement for new, increasing, unchanged, decreasing, and disappearing classifications was 70%, 70%, 85%, 63%, and 90%.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Quantitative single-timepoint or longitudinal analysis of lesion ROIs on adult PET/CT, including volume, density, and tracer-uptake changes, with a report used as an adjunct to local image interpretation.
Centralized quantitative ROI segmentation, registration, longitudinal change analysis, and report generation as an adjunct to local interpretation; clinicians responsible for patient care or local image interpretation do not directly operate the device.
CT and PET/CT volumetric images supported by ACR/NEMA DICOM 3.0, with ROIs identified by the software or imported from validated tools or qualified manual contouring. Multi-timepoint use recommends adult PET/CT after FDG with the second FDG administration no more than 12 months after the first; single-timepoint use also covers FDG-, PSMA-, or SSTR-targeted PET drugs per approved labeling.
A TRAQinform Report with ROI anatomic location, contours and 2D/3D renderings, volumes and volume changes, CT radio-density measures and changes, PET SUVmax/SUVtotal/SUVmean/SUVhetero measures and changes, heterogeneity measures, and computed classification of quantitative FDG ROI changes.
Adult oncology and nuclear-medicine PET/CT workflow; recommended use is for adults aged 22 years or older, with local interpretation performed before and independently of the report.
Trained medical professionals including oncologists, nuclear radiologists or physicians, medical imaging technologists, dosimetrists, and physicists; the report is generated by the manufacturer and signed by a U.S. board-certified physician qualified in nuclear radiology or medicine.
The device is not intended to diagnose disease, replace CT or PET/CT interpretation, recommend treatment, or replace professional judgment. Binary patient-level progression or non-progression decisions are not established without multidisciplinary review; care-relevant discrepancies require subject-matter review and neutral or blinded adjudication. The stated age, tracer, and timepoint conditions apply.
FDA testing included component verification, test-retest analysis, and a pivotal reader study. Test-retest used 31 non-small-cell-lung-cancer patients with two FDG PET/CT studies within one week; limits of repeatability were SUVmax -27.0% to 56.8%, SUVmean -20.2% to 38.5%, SUVtotal -54.1% to 144.5%, and volume -52.6% to 113.9%. The pivotal study used 103 patients with two sequential scans, three oncologist evaluators, and scans from at least 10 imaging centers in at least 3 U.S. states. In a 32-patient reevaluation subset, the 95% CI for overall percent agreement was 41%-76%, positive percent agreement was 14/18 (78%), and negative percent agreement was 5/14 (36%); ROI-level agreement for new, increasing, unchanged, decreasing, and disappearing classifications was 70%, 70%, 85%, 63%, and 90%.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA testing included component verification, test-retest analysis, and a pivotal reader study. Test-retest used 31 non-small-cell-lung-cancer patients with two FDG PET/CT studies within one week; limits of repeatability were SUVmax -27.0% to 56.8%, SUVmean -20.2% to 38.5%, SUVtotal -54.1% to 144.5%, and volume -52.6% to 113.9%. The pivotal study used 103 patients with two sequential scans, three oncologist evaluators, and scans from at least 10 imaging centers in at least 3 U.S. states. In a 32-patient reevaluation subset, the 95% CI for overall percent agreement was 41%-76%, positive percent agreement was 14/18 (78%), and negative percent agreement was 5/14 (36%); ROI-level agreement for new, increasing, unchanged, decreasing, and disappearing classifications was 70%, 70%, 85%, 63%, and 90%.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
TRAQinform IQ regulatory performance study summary
DesignReader Study
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K233998
IndependenceIndependence not established
K233998
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K233998. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: CT and PET/CT volumetric images supported by ACR/NEMA DICOM 3.0, with ROIs identified by the software or imported from validated tools or qualified manual contouring. Multi-timepoint use recommends adult PET/CT after FDG with the second FDG administration no more than 12 months after the first; single-timepoint use also covers FDG-, PSMA-, or SSTR-targeted PET drugs per approved labeling.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA packet specifies CT and PET/CT DICOM 3.0 input and operation in a cloud environment; exact local PACS, RIS, EHR, interface, version, hosting, and security controls are not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes the TRAQinform IQ software as operating in a secure cloud environment. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "The TRAQinform IQ software operates in a secure cloud environment.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: A TRAQinform Report with ROI anatomic location, contours and 2D/3D renderings, volumes and volume changes, CT radio-density measures and changes, PET SUVmax/SUVtotal/SUVmean/SUVhetero measures and changes, heterogeneity measures, and computed classification of quantitative FDG ROI changes.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: A TRAQinform Report with ROI anatomic location, contours and 2D/3D renderings, volumes and volume changes, CT radio-density measures and changes, PET SUVmax/SUVtotal/SUVmean/SUVhetero measures and changes, heterogeneity measures, and computed classification of quantitative FDG ROI changes.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes the TRAQinform IQ software as operating in a secure cloud environment. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The TRAQinform IQ software operates in a secure cloud environment.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The FDA packet specifies CT and PET/CT DICOM 3.0 input and operation in a cloud environment; exact local PACS, RIS, EHR, interface, version, hosting, and security controls are not established.
ACR AI Central provides an exact-submission model card for TRAQinform IQ; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K233998 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: syngo.via MI Workflows, Scenium, and syngo MBF provide PET, SPECT, nuclear-medicine, CT, and MR viewing, manipulation, quantification, longitudinal comparison, and analysis for oncology, cardiology, neurology, organ function, and selected radiation-planning support.
Authorized purpose: Opulus Lymphoma Precision segments and visualizes lesions and measures total metabolic tumor volume in whole-body FDG-PET/CT for patients already diagnosed with FDG-avid lymphoma; trained physicians can accept/reject annotated output, but radiologist review makes the final interpretation and the device is not a screening/diagnostic substitute.
Authorized purpose: uMI Panorama GS combines 148 cm axial-field-of-view PET with CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and registered or fused PET/CT images supporting detection, localization, diagnosis, staging, restaging, treatment planning, and treatment-response evaluation. K241585 adds reconstruction, respiratory-motion, CT-less attenuation-correction, quantitative-normalization, quality-control, and AI-expanded-field-of-view functions.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.